Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome
Primary Purpose
Obesity, Prader-Willi Syndrome
Status
Completed
Phase
Locations
Study Type
Observational
Intervention
Sponsored by
About this trial
This is an observational trial for Obesity focused on measuring adiponectin, adiponectin receptor, Prader-Willi syndrome
Eligibility Criteria
Inclusion Criteria:
- children with Prader-willi syndrome
- children with simple obesity
Exclusion Criteria:
- subjects with diabetes mellitus (fasting plasma glucose > 126 mg/dL with a 2-h oral glucose tolerance test value of >200 mg/dl)
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00800852
First Posted
November 30, 2008
Last Updated
December 1, 2008
Sponsor
Samsung Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00800852
Brief Title
Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome
Official Title
Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome
Study Type
Observational
2. Study Status
Record Verification Date
November 2008
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Samsung Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The inflammatory process is involved in the pathogenesis of obesity. Prader-Willi syndrome (PWS) is a genetic model of syndromic obesity. Adiponectin is an adipokine with potent anti-inflammatory properties, and its effect is mediated through adiponectin receptors 1 (adipoR1) and 2 (adipoR2).
Objective of this study is to compare the expression of adipoR1, adipoR2, and adiponectin in peripheral blood mononuclear cells (PBMCs) in PWS children and obese control and to correlate receptor expression with insulin sensitivity and obesity-related parameters.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Prader-Willi Syndrome
Keywords
adiponectin, adiponectin receptor, Prader-Willi syndrome
7. Study Design
10. Eligibility
Sex
All
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
children with Prader-willi syndrome
children with simple obesity
Exclusion Criteria:
subjects with diabetes mellitus (fasting plasma glucose > 126 mg/dL with a 2-h oral glucose tolerance test value of >200 mg/dl)
Study Population Description
Fourteen children with PWS and control subjects
Sampling Method
Probability Sample
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Don-Kyu Jin, M.D.
Organizational Affiliation
Samsung Medical Center, Sungkyunkwan Uiversity School of Medicine
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome
We'll reach out to this number within 24 hrs